Overactive Bladder (OAB), Urge Incontinence
Conditions
Keywords
mirabegron
Brief summary
The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of overactive bladder (OAB) in Chinese participants. This study also evaluated the safety of mirabegron for the treatment of OAB in Chinese participants, evaluated other efficacy variables of mirabegron for the treatment of OAB and explored different mirabegron starting doses.
Detailed description
The study followed an open-label, randomized, 12-week, prospective, interventional post-authorization design for the treatment of OAB in 249 Chinese participants. Each eligible participant took part in a 12-week treatment period. Treatments were administered once daily orally after a meal during a 12-week, open-label treatment period. Study visits took place at weeks 4, 8 and 12. For the 25 mg mirabegron group, a dose escalation to 50 mg was permitted on visit 3 and visit 4 at the investigators' discretion. 15 study sites across China enrolled participants.
Interventions
DRUGmirabegron
Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet
Sponsors
Astellas Pharma China, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
This was an open label study.
Intervention model description
Participants fulfilling the screening inclusion/exclusion criteria were randomized in a 2:1 ratio, 50 mg mirabegron and 25 mg mirabegron, using a computer-generated randomization to reduce selection bias.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant should exhibit symptoms of OAB for at least 12 weeks before initiation of the screening period. * Participant should have an average of ≥ 8 micturitions/24 hours. * Participant should have an average of ≥ 1 episode of grade 3 or 4 (PPIUS) urgency or urgency incontinence/24 hours, during a 3-day micturition diary period. * Female participant is not pregnant and at least one of the following conditions apply: * Not a woman of childbearing potential (WOCBP) * WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 30 days after final investigational product (IP) administration. * Female participant must agree not to breastfeed starting at screening and throughout the study period and for 30 days after final IP administration. * Female participant must not donate ova starting at first dose of investigational product (IP) and throughout the study period and for 30 days after final IP administration. * Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and 30 days after final IP administration. * Male participant must not donate sperm during the treatment period and for 30 days after final IP administration. * Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 30 days after final IP administration. * Participant agrees not to participate in another interventional study while participating in the present study, defined as 28 days prior screening until completion of the last study visit.
Exclusion criteria
Exclusion at Visit 1/Week -2 (Screening) * Participant has stress urinary incontinence as a predominant symptom. * Participant has an average total daily urine volume \> 3000 mL (as recorded in a 3-day voiding diary period). * Participant has indwelling catheter or practices intermittent self-catheterization. * Participant has neurogenic detrusor overactivity or indicated pathology other than OAB. * Participant as monosymptomatic enuresis. * Participant has post void residual (PVR) volume of ≥ 100 mL or a clinically significant lower urinary tract obstructive disease, except if successfully treated. * Participant has anatomical anomalies (surgically treated or untreated) that affect lower urinary tract function. * Participant with hematuria on dipstick test. In the case of hematuria on dipstick test in a female during menstruation, the test can be repeated before randomization (after the end of menstruation). * Participant has lower urinary tract stones or clinically significant kidney stones requiring treatment. * Participant has interstitial cystitis. * Participant has suffered from chronic urinary tract infection (UTI) or has had more than 3 ETIs in the 2 months prior to visit 1/week -1 to -2 (screening). * Participant has uncontrolled hypertension (sitting systolic blood pressure \[SBP\] ≥ 180 mmHg or diastolic blood pressure \[DBP\] ≥ 110 mmHg). * Participant has pulse rate ≥ 110 beats per minute (bpm) or \<50 bpm. * Participant has corrected QT interval by Fredericia (QTcF) \> 440 msec on screening ECG or a risk of QT prolongation (e.g., hypokalemia, long QT syndrome \[LQTS\] or family history of LQTS or exercise-induced syncope). * Participant's aspartate aminotransferase (AST) or alanine aminotransferase (ALT) is ≥ 2 × upper limit of normal (ULN) or total bilirubin (TBL) is ≥ 1.5 × ULN according to age and sex (participants with Gilbert's syndrome are excepted from the bilirubin threshold). * Participant has moderate or severe renal impairment. * Participant has a symptomatic (symptoms can include pain, fever, hematuria, new onset foul-smelling urine) UTI. Note: if the UTI is treated successfully (clinical recovery: confirmed by dipstick test and repeated dipstick test after 14 days \[both should be negative\]), the participant can be rescreened. * Participant has a history or presence of any malignancy (previous or current diagnosis of bladder or prostate cancer). * Participant uses any drugs that are sensitive cytochrome P450 2D6 (CYP2D6) substrates with a narrow therapeutic index or sensitive P-glycoprotein (P-gp) substrates after the start of washout. * Participant is using or has used prohibited prior and/or concomitant medication(s). In case α1-AR antagonists, 5α-reductase inhibitors (5-ARIs) and Phosphodiesterase type 5 inhibitors (PED-Is) are used for Benign Prostatic Hyperplasia(BPH), participant can be included in the study. * Participant has known or suspected hypersensitivity to mirabegron or any components of the formulations used. * Participants previously treated for OAB including medication and nondrug treatment. If the treatment stopped for 2 weeks or more prior to the screening visit, participants can be included in the study. * Participant has participated in another clinical study (and/or participant has received any investigational therapy within 30 days (or 5 half-lives of the drug, or the limit set by national law, whichever is longer) prior to visit 1/week -1 to -2 (screening). * Participant has constipation as defined by the Rome IV criteria that cannot be successfully treated prior to study entry. * Female participant who has been pregnant within 6 months prior to screening or breastfeeding within 3 months prior to screening. * Participants has a positive serology test for hepatitis A virus (HAV) antibodies (immunoglobulin M \[IgM\]), hepatitis B core (HBc) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, antibodies to human immunodeficiency virus (HIV) or syphilis at screening. * Participant is an employee of Astellas, the study-related contract research organizations (CROs) or the clinical unit. * Participant has any condition which makes the participant unsuitable for study participation. Additional Exclusion at Visit 2/Week 0 (Baseline) * Participant has stress urinary incontinence as a predominant symptom. * Participant has an average total daily urine volume \> 3000 mL (as recorded in a 3-day voiding diary period). * Participant has monosymptomatic enuresis confirmed by the bladder e-diary. * Participant suffers from a symptomatic (symptoms can include pain, fever, hematuria, new onset foul-smelling urine) UTI. Note: if a symptomatic UTI is present, all visit 2/week 0 (baseline) assessments must be postponed until the UTI is successfully treated (clinical recovery: confirmed by dipstick test and repeated dipstick test after 14 days \[both should be negative\]). The postponed visit 2/week 0 (baseline) should be within 14 days of the intended visit 2/week 0 (baseline). * Participant with hematuria on dipstick test. In the case of hematuria on dipstick test in a female during menstruation, the test can be repeated before randomization (after the end of menstruation). * Participant has uncontrolled hypertension (sitting SBP ≥ 180 mmHg or DBP ≥ 110 mmHg). * Any reason that makes the participant unsuitable for study participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline (CFB) to the End of 12-Week Treatment Period in Mean Number of Micturition/24 Hours in Mirabegron 50 mg Group | Baseline, week 12 | A micturition was defined as any voluntary act of passing urine (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated as the average number of times a participant urinated per day during the 3-day micturition diary period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline to Week 12 in Post Void Residual (PVR) Volume | Baseline, week 12 | PVR was assessed by ultrasonography. |
| Change From Baseline in Mean Number of Grade 3 or 4 Patient Perception of Intensity of Urgency Scale (PPIUS) Urgency Episodes Per 24 Hours | Baseline and weeks 4, 8, and 12 | Urgency was defined as a complaint of a sudden, compelling desire to pass urine, which was difficult to defer. An urgency episode was defined as any micturition or incontinence episode with a severity of grade 3 or 4, assessed by participants based on the PPIUS, where grade 0 = No urgency; grade 1 = Mild urgency; grade 2 = Moderate urgency, could delay voiding a short while; grade 3 = Severe urgency, could not delay voiding; grade 4 = Urge incontinence, leaked before arriving to the toilet. The mean number of urgency episodes (grade 3 and/or 4) per day was calculated as the average number of times a participant recorded an urgency episode (grade 3 and/or 4) with or without incontinence per day during the 3-day micturition diary period. |
| Change From Baseline in Mean Number of Daytime Incontinence Episodes Per 24 Hours | Baseline and weeks 4, 8, and 12 | An incontinence episode was defined as an episode with any involuntary loss of urine. Daytime was defined as time between waking up in the morning and going to sleep later the same day or next day. The mean number of incontinence episodes was determined using the patient diary data recorded by the participant in the 7 days prior to baseline visit and at various specified time-intervals. |
| Number of Participants With Treatment Emergent Adverse Events | From first dose up to 30 days after last dose (up to week 16) | AE was defined as any untoward medical occurrence in a participant administered a study drug or had undergone study procedures and which did not necessarily have had a causal relationship with the treatment. An abnormality identified during a medical test (e.g., laboratory parameter, vital sign, Electrocardiography (ECG) data, and physical exam) was defined as an AE only if the abnormality induced clinical signs or symptoms or requires active intervention or requires interruption or discontinuation of study medication or the abnormality or investigational value was clinically significant in the opinion of the investigator. Treatment emergent AE was defined as an AE observed after starting administration of the IP and 30 days after the final administration of study drug. |
| Change From Baseline in Mean Number of Urge Incontinence Episodes Per 24 Hours | Baseline and weeks 4, 8, and 12 | An incontinence episode was defined as an episode with any involuntary loss of urine. The mean number of urge incontinence episodes per 24 hours was determined using the patient diary data recorded by the participant in the 7 days prior to baseline visit and at various specified time-intervals. |
| Change From Baseline in OAB Symptom Score (OABSS) | Baseline and weeks 4, 8, and 12 | The OABSS questionnaire was a questionnaire completed by participants with 4 questions regarding their OAB symptoms: Daytime Frequency (How many times do you typically urinate from waking in the morning until sleeping at night? where scores range from 0-2), Nighttime Frequency (How many times do you typically wake up to urinate from sleeping at night until waking in the morning? where scores range from 0-3), Urgency (How often do you have a sudden desire to urinate, which is difficult to defer? where scores range from 0-5), Urgency Incontinence (How often do you leak urine because you cannot defer the sudden desire to urinate? where scores range from 0-5). The total score ranges from 0 to 15 with higher score indicating more symptoms. |
| Change From Baseline in Mean Number of Micturition Per 24 Hours | Baseline and weeks 4 and 8 | A micturition was defined as any voluntary act of passing urine (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated as the average number of times a participant urinated per day during the 3-day micturition diary period. |
| Change From Baseline in Mean Number of Nighttime Incontinence Episodes Per 24 Hours | Baseline and weeks 4, 8, and 12 | An incontinence episode was defined as an episode with any involuntary loss of urine. Nightime was defined as time between between going to sleep on a day and waking up on the same or next day. The mean number of incontinence episodes was determined using the patient diary data recorded by the participant in the 7 days prior to baseline visit and at various specified time-intervals. |
Countries
China
Participant flow
Recruitment details
Participants were enrolled at study sites in China.
Pre-assignment details
Participants with symptoms of overactive bladder (OAB) for at least 12 weeks before initiation of the screening period and who met all of the inclusion and none of the exclusion criteria were enrolled in this study.
Participants by arm
| Arm | Count |
|---|---|
| Mirabegron 25 mg Participants received single oral dose of mirabegron 25 mg tablet once daily, at the same time after a meal for a duration of 12 weeks. Dose escalation to 50 mg was permitted at Visit 3 (Week 4) or Visit 4 (Week 8) at the discretion of investigator. | 84 |
| Mirabegron 50 mg Participants received single oral dose of mirabegron 50 mg tablet once daily, at the same time after a meal for a duration of 12 weeks. | 165 |
| Total | 249 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 1 | 4 |
| Overall Study | Lack of Efficacy | 0 | 1 |
| Overall Study | Miscellaneous | 0 | 3 |
| Overall Study | Protocol Violation | 2 | 0 |
| Overall Study | Withdrawal by Subject | 3 | 4 |
Baseline characteristics
| Characteristic | Mirabegron 25 mg | Mirabegron 50 mg | Total |
|---|---|---|---|
| Age, Continuous | 48.1 Years STANDARD_DEVIATION 16 | 50.6 Years STANDARD_DEVIATION 14.6 | 49.7 Years STANDARD_DEVIATION 15.1 |
| Mean Number of Micturitions per 24 hours | 11.8 micturitions per 24 hours STANDARD_DEVIATION 6.36 | 11.77 micturitions per 24 hours STANDARD_DEVIATION 5.47 | 11.78 micturitions per 24 hours STANDARD_DEVIATION 5.76 |
| Race/Ethnicity, Customized Chinese Ethnicity | 84 Participants | 165 Participants | 249 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 84 Participants | 165 Participants | 249 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Female | 65 Participants | 120 Participants | 185 Participants |
| Sex: Female, Male Male | 19 Participants | 45 Participants | 64 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 44 | 0 / 39 | 0 / 39 | 0 / 165 |
| other Total, other adverse events | 1 / 44 | 0 / 39 | 3 / 39 | 6 / 165 |
| serious Total, serious adverse events | 3 / 44 | 1 / 39 | 2 / 39 | 8 / 165 |
Outcome results
Primary
Change From Baseline (CFB) to the End of 12-Week Treatment Period in Mean Number of Micturition/24 Hours in Mirabegron 50 mg Group
A micturition was defined as any voluntary act of passing urine (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated as the average number of times a participant urinated per day during the 3-day micturition diary period.
Time frame: Baseline, week 12
Population: Full Analysis set (FAS) included all participants who were randomized and received at least 1 dose of investigational product (IP) and had at least 1 post baseline measurement for mean number of micturitions per 24 hours. Participants with available data were analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Mirabegron 50 mg | Change From Baseline (CFB) to the End of 12-Week Treatment Period in Mean Number of Micturition/24 Hours in Mirabegron 50 mg Group | -3.76 micturitions per 24 hours | Standard Deviation 0.4 |
Comparison: Week 12p-value: <0.00195% CI: [-4.3, -3.16]MMRM
Secondary
Change From Baseline in Mean Number of Daytime Incontinence Episodes Per 24 Hours
An incontinence episode was defined as an episode with any involuntary loss of urine. Daytime was defined as time between waking up in the morning and going to sleep later the same day or next day. The mean number of incontinence episodes was determined using the patient diary data recorded by the participant in the 7 days prior to baseline visit and at various specified time-intervals.
Time frame: Baseline and weeks 4, 8, and 12
Population: FAS population with available data at specified time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Mirabegron 50 mg | Change From Baseline in Mean Number of Daytime Incontinence Episodes Per 24 Hours | Change at Week 4 | -0.48 incontinence episodes per 24 hours | Standard Deviation 1.82 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Daytime Incontinence Episodes Per 24 Hours | Change at Week 8 | -1.06 incontinence episodes per 24 hours | Standard Deviation 1.85 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Daytime Incontinence Episodes Per 24 Hours | Change at Week 12 | -1.03 incontinence episodes per 24 hours | Standard Deviation 1.77 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Daytime Incontinence Episodes Per 24 Hours | Change at Week 4 | -0.77 incontinence episodes per 24 hours | Standard Deviation 2.47 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Daytime Incontinence Episodes Per 24 Hours | Change at Week 8 | -0.89 incontinence episodes per 24 hours | Standard Deviation 2.59 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Daytime Incontinence Episodes Per 24 Hours | Change at Week 12 | -0.97 incontinence episodes per 24 hours | Standard Deviation 2.63 |
Comparison: Week 4p-value: <0.00195% CI: [-0.88, -0.44]MMRM
Comparison: Week 4p-value: <0.00195% CI: [-0.97, -0.65]MMRM
Comparison: Week 8p-value: <0.00195% CI: [-1.17, -0.58]MMRM
Comparison: Week 8p-value: <0.00195% CI: [-1.1, -0.78]MMRM
Comparison: Week 12p-value: <0.00195% CI: [-1.35, -0.71]MMRM
Comparison: Week 12p-value: <0.00195% CI: [-1.14, -0.81]MMRM
Secondary
Change From Baseline in Mean Number of Grade 3 or 4 Patient Perception of Intensity of Urgency Scale (PPIUS) Urgency Episodes Per 24 Hours
Urgency was defined as a complaint of a sudden, compelling desire to pass urine, which was difficult to defer. An urgency episode was defined as any micturition or incontinence episode with a severity of grade 3 or 4, assessed by participants based on the PPIUS, where grade 0 = No urgency; grade 1 = Mild urgency; grade 2 = Moderate urgency, could delay voiding a short while; grade 3 = Severe urgency, could not delay voiding; grade 4 = Urge incontinence, leaked before arriving to the toilet. The mean number of urgency episodes (grade 3 and/or 4) per day was calculated as the average number of times a participant recorded an urgency episode (grade 3 and/or 4) with or without incontinence per day during the 3-day micturition diary period.
Time frame: Baseline and weeks 4, 8, and 12
Population: FAS population with available data at specified time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Mirabegron 50 mg | Change From Baseline in Mean Number of Grade 3 or 4 Patient Perception of Intensity of Urgency Scale (PPIUS) Urgency Episodes Per 24 Hours | Change at Week 4 | -2.09 urgency episodes per 24 hours | Standard Deviation 2.35 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Grade 3 or 4 Patient Perception of Intensity of Urgency Scale (PPIUS) Urgency Episodes Per 24 Hours | Change at Week 8 | -2.66 urgency episodes per 24 hours | Standard Deviation 2.57 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Grade 3 or 4 Patient Perception of Intensity of Urgency Scale (PPIUS) Urgency Episodes Per 24 Hours | Change at Week 12 | -2.57 urgency episodes per 24 hours | Standard Deviation 1.92 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Grade 3 or 4 Patient Perception of Intensity of Urgency Scale (PPIUS) Urgency Episodes Per 24 Hours | Change at Week 4 | -2.53 urgency episodes per 24 hours | Standard Deviation 5.54 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Grade 3 or 4 Patient Perception of Intensity of Urgency Scale (PPIUS) Urgency Episodes Per 24 Hours | Change at Week 8 | -2.98 urgency episodes per 24 hours | Standard Deviation 5.78 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Grade 3 or 4 Patient Perception of Intensity of Urgency Scale (PPIUS) Urgency Episodes Per 24 Hours | Change at Week 12 | -3.55 urgency episodes per 24 hours | Standard Deviation 5.75 |
Comparison: Week 12p-value: <0.00195% CI: [-4.06, -3.12]MMRM
Comparison: Week 4p-value: <0.00195% CI: [-3.25, -1.99]MMRM
Comparison: Week 4p-value: <0.00195% CI: [-2.93, -2.02]MMRM
Comparison: Week 8p-value: <0.00195% CI: [-3.96, -2.3]MMRM
Comparison: Week 8p-value: <0.00195% CI: [-3.39, -2.47]MMRM
Comparison: Week 12p-value: <0.00195% CI: [-4.37, -2.56]MMRM
Secondary
Change From Baseline in Mean Number of Micturition Per 24 Hours
A micturition was defined as any voluntary act of passing urine (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated as the average number of times a participant urinated per day during the 3-day micturition diary period.
Time frame: Baseline and weeks 4 and 8
Population: FAS population with available data at specified time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Mirabegron 50 mg | Change From Baseline in Mean Number of Micturition Per 24 Hours | Change at Week 4 | -2.06 micturitions per 24 hours | Standard Deviation 2.64 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Micturition Per 24 Hours | Change at Week 8 | -2.65 micturitions per 24 hours | Standard Deviation 2.55 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Micturition Per 24 Hours | Change at Week 4 | -2.44 micturitions per 24 hours | Standard Deviation 4.62 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Micturition Per 24 Hours | Change at Week 8 | -3.01 micturitions per 24 hours | Standard Deviation 4.76 |
Comparison: Week 4p-value: <0.00195% CI: [-2.73, -1.21]MMRM
Comparison: Week 4p-value: <0.00195% CI: [-2.9, -1.81]MMRM
Comparison: Week 8p-value: <0.00195% CI: [-4.2, -2.2]MMRM
Comparison: Week 8p-value: <0.00195% CI: [-3.47, -2.37]MMRM
Secondary
Change From Baseline in Mean Number of Nighttime Incontinence Episodes Per 24 Hours
An incontinence episode was defined as an episode with any involuntary loss of urine. Nightime was defined as time between between going to sleep on a day and waking up on the same or next day. The mean number of incontinence episodes was determined using the patient diary data recorded by the participant in the 7 days prior to baseline visit and at various specified time-intervals.
Time frame: Baseline and weeks 4, 8, and 12
Population: FAS population with available data at specified time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Mirabegron 50 mg | Change From Baseline in Mean Number of Nighttime Incontinence Episodes Per 24 Hours | Change at Week 4 | -0.37 incontinence episodes per 24 hours | Standard Deviation 1.11 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Nighttime Incontinence Episodes Per 24 Hours | Change at Week 8 | -0.67 incontinence episodes per 24 hours | Standard Deviation 1.5 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Nighttime Incontinence Episodes Per 24 Hours | Change at Week 12 | -0.42 incontinence episodes per 24 hours | Standard Deviation 0.91 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Nighttime Incontinence Episodes Per 24 Hours | Change at Week 4 | -0.47 incontinence episodes per 24 hours | Standard Deviation 3.06 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Nighttime Incontinence Episodes Per 24 Hours | Change at Week 8 | -0.45 incontinence episodes per 24 hours | Standard Deviation 3.05 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Nighttime Incontinence Episodes Per 24 Hours | Change at Week 12 | -0.54 incontinence episodes per 24 hours | Standard Deviation 3.18 |
Comparison: Week 4p-value: <0.00195% CI: [-0.58, -0.37]MMRM
Comparison: Week 4p-value: <0.00195% CI: [-0.53, -0.38]MMRM
Comparison: Week 8p-value: <0.00195% CI: [-0.67, -0.39]MMRM
Comparison: Week 8p-value: <0.00195% CI: [-0.52, -0.37]MMRM
Comparison: Week 12p-value: <0.00195% CI: [-0.68, -0.38]MMRM
Comparison: Week 12p-value: <0.00195% CI: [-0.6, -0.45]MMRM
Secondary
Change From Baseline in Mean Number of Urge Incontinence Episodes Per 24 Hours
An incontinence episode was defined as an episode with any involuntary loss of urine. The mean number of urge incontinence episodes per 24 hours was determined using the patient diary data recorded by the participant in the 7 days prior to baseline visit and at various specified time-intervals.
Time frame: Baseline and weeks 4, 8, and 12
Population: FAS population with available data at specified time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Mirabegron 50 mg | Change From Baseline in Mean Number of Urge Incontinence Episodes Per 24 Hours | Change at Week 4 | -0.67 urge incontinence episodes per 24 hours | Standard Deviation 1.71 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Urge Incontinence Episodes Per 24 Hours | Change at Week 8 | -1.15 urge incontinence episodes per 24 hours | Standard Deviation 2.38 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Urge Incontinence Episodes Per 24 Hours | Change at Week 12 | -0.92 urge incontinence episodes per 24 hours | Standard Deviation 1.71 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Urge Incontinence Episodes Per 24 Hours | Change at Week 4 | -1.18 urge incontinence episodes per 24 hours | Standard Deviation 5.02 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Urge Incontinence Episodes Per 24 Hours | Change at Week 8 | -1.25 urge incontinence episodes per 24 hours | Standard Deviation 5.06 |
| Mirabegron 50 mg | Change From Baseline in Mean Number of Urge Incontinence Episodes Per 24 Hours | Change at Week 12 | -1.36 urge incontinence episodes per 24 hours | Standard Deviation 5.23 |
Comparison: Week 4p-value: <0.00195% CI: [-1.31, -0.9]MMRM
Comparison: Week 4p-value: <0.00195% CI: [-1.25, -0.96]MMRM
Comparison: Week 8p-value: <0.00195% CI: [-1.53, -0.99]MMRM
Comparison: Week 8p-value: <0.00195% CI: [-1.34, -1.05]MMRM
Comparison: Week 12p-value: <0.00195% CI: [-1.54, -0.96]MMRM
Comparison: Week 12p-value: <0.00195% CI: [-1.42, -1.12]MMRM
Secondary
Change From Baseline in OAB Symptom Score (OABSS)
The OABSS questionnaire was a questionnaire completed by participants with 4 questions regarding their OAB symptoms: Daytime Frequency (How many times do you typically urinate from waking in the morning until sleeping at night? where scores range from 0-2), Nighttime Frequency (How many times do you typically wake up to urinate from sleeping at night until waking in the morning? where scores range from 0-3), Urgency (How often do you have a sudden desire to urinate, which is difficult to defer? where scores range from 0-5), Urgency Incontinence (How often do you leak urine because you cannot defer the sudden desire to urinate? where scores range from 0-5). The total score ranges from 0 to 15 with higher score indicating more symptoms.
Time frame: Baseline and weeks 4, 8, and 12
Population: FAS population with available data at specified time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Mirabegron 50 mg | Change From Baseline in OAB Symptom Score (OABSS) | Change at Week 12 | -6.19 scores on a scale | Standard Deviation 2.72 |
| Mirabegron 50 mg | Change From Baseline in OAB Symptom Score (OABSS) | Change at Week 4 | -2.91 scores on a scale | Standard Deviation 2.85 |
| Mirabegron 50 mg | Change From Baseline in OAB Symptom Score (OABSS) | Change at Week 8 | -5.34 scores on a scale | Standard Deviation 2.69 |
| Mirabegron 50 mg | Change From Baseline in OAB Symptom Score (OABSS) | Change at Week 4 | -3.01 scores on a scale | Standard Deviation 2.85 |
| Mirabegron 50 mg | Change From Baseline in OAB Symptom Score (OABSS) | Change at Week 8 | -4.29 scores on a scale | Standard Deviation 3.01 |
| Mirabegron 50 mg | Change From Baseline in OAB Symptom Score (OABSS) | Change at Week 12 | -5.43 scores on a scale | Standard Deviation 3.04 |
Comparison: Week 4p-value: <0.00195% CI: [-3.5, -2.43]MMRM
Comparison: Week 4p-value: <0.00195% CI: [-3.44, -2.65]MMRM
Comparison: Week 8p-value: <0.00195% CI: [-5.8, -4.39]MMRM
Comparison: Week 8p-value: <0.00195% CI: [-4.7, -3.9]MMRM
Comparison: Week 12p-value: <0.00195% CI: [-6.78, -5.24]MMRM
Comparison: Week 12p-value: <0.00195% CI: [-5.82, -4.98]MMRM
Secondary
Change From Baseline to Week 12 in Post Void Residual (PVR) Volume
PVR was assessed by ultrasonography.
Time frame: Baseline, week 12
Population: SAF population with available data at specified time point.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Mirabegron 50 mg | Change From Baseline to Week 12 in Post Void Residual (PVR) Volume | -2.7 milliliter | Standard Deviation 26.3 |
| Mirabegron 50 mg | Change From Baseline to Week 12 in Post Void Residual (PVR) Volume | -1.3 milliliter | Standard Deviation 24.5 |
Secondary
Number of Participants With Treatment Emergent Adverse Events
AE was defined as any untoward medical occurrence in a participant administered a study drug or had undergone study procedures and which did not necessarily have had a causal relationship with the treatment. An abnormality identified during a medical test (e.g., laboratory parameter, vital sign, Electrocardiography (ECG) data, and physical exam) was defined as an AE only if the abnormality induced clinical signs or symptoms or requires active intervention or requires interruption or discontinuation of study medication or the abnormality or investigational value was clinically significant in the opinion of the investigator. Treatment emergent AE was defined as an AE observed after starting administration of the IP and 30 days after the final administration of study drug.
Time frame: From first dose up to 30 days after last dose (up to week 16)
Population: Safety Analysis Set (SAF) consisted of all participants who took at least 1 dose of IP.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Mirabegron 50 mg | Number of Participants With Treatment Emergent Adverse Events | 18 participants |
| Mirabegron 50 mg | Number of Participants With Treatment Emergent Adverse Events | 58 participants |